當前位置:廣州健侖生物科技有限公司>>生物試劑>>Certest>> 西班牙Certest滅活沙門氏菌副傷寒B抗原(天然提取物)
西班牙Certest滅活沙門氏菌副傷寒B抗原(天然提取物)
廣州健侖生物科技有限公司
廣州健侖長期供應各種生物原料,主要代理品牌:西班牙Certest。
主要產品包括各種生物單克隆抗原抗體、重組蛋白。
西班牙Certest滅活沙門氏菌副傷寒B抗原(天然提取物)
我司還提供其它進口或國產試劑盒:登革熱、瘧疾、流感、A鏈球菌、合胞病毒、腮病毒、乙腦、寨卡、黃熱病、基孔肯雅熱、克錐蟲病、違禁品濫用、肺炎球菌、軍團菌、化妝品檢測、食品安全檢測等試劑盒以及日本生研細菌分型診斷血清、德國SiFin診斷血清、丹麥SSI診斷血清等產品。
歡迎咨詢
歡迎咨詢2042552662
【產品介紹】
貨號 | 產品名稱 | 規格 | 英文名稱 |
MT-18EH30 | 阿米巴原蟲抗體(克隆H30) | x1mg | Anti-Entamoeba Mab (clone EH30) |
MT-25ETV | 腸道病毒VP1重組蛋白 | x1mg | Enterovirus VP1 recombinant protein |
MT-18EV5 | 腸道病毒抗體(克隆EV5) | x1mg | Anti-Enterovirus Mab (clone EV5) |
MT-25STX | 大腸桿菌O157 VT1重組蛋白 | x1mg | E. coli O157 VT1 recombinant protein |
MT-25VT2 | 大腸桿菌O157 VT2重組蛋白 | x1mg | E. coli O157 VT2 recombinant protein |
MT-18E10 | 大腸桿菌O157抗體(克隆E10) | x1mg | Anti-E. coli O157 Mab (clone E10) |
MT-18SN3 | 肺炎鏈球菌單克隆抗體(克隆SN3) | x1mg | Anti-Streptococcus pneumoniae Mab (clone SN3) |
MT-18SN4 | 肺炎鏈球菌單克隆抗體(克隆SN4) | x1mg | Anti-Streptococcus pneumoniae Mab (clone SN4) |
MT-16CP14 | 鈣結合蛋白單克隆抗體(克隆CP14) | x1mg | Anti-Calprotectin Mab (clone CP14) |
MT-18RV3 | 呼吸道合胞病毒單抗(克隆RV3) | x1mg | Anti-RSV Mab (clone RV3) |
MT-18RV4 | 呼吸道合胞病毒單抗(克隆RV4) | x1mg | Anti-RSV Mab (clone RV4) |
MT-25RSV | 呼吸道合胞病毒重組融合蛋白 | x1mg | RSV recombinant fusion protein |
MT-18Y77 | 甲型流感病毒單抗(克隆Y77) | x1mg | Anti-Influenza A Mab (clone Y77) |
MT-25FAN | 甲型流感病毒重組核蛋白 | x1mg | Influenza A recombinant nucleoprotein |
MT-16G18 | 賈第鞭毛蟲抗體(克隆G18) | x1mg | Anti-Giardia Mab trophozoite protein (clone G18) |
MT-16G22 | 賈第鞭毛蟲抗體(克隆G22) | x1mg | Anti-Giardia Mab trophozoite protein (clone G22) |
MT-25A1G | 賈第蟲腸道滋養體重組蛋白 | x1mg | Giardia intestinalis trophozoite recombinant protein |
MT-25GCP | 賈第蟲腸囊菌重組蛋白 | x1mg | Giardia intestinalis cyst recombinant protein |
MT-25GDH | 艱難梭菌GDH重組蛋白 | x1mg | Clostridium difficile GDH recombinant protein |
MT-18TA5 | 艱難梭菌毒素A抗(克隆TA5) | x1mg | Anti-CD Toxin A Mab (clone TA5) |
MT-18TA7 | 艱難梭菌毒素A抗(克隆TA7) | x1mg | Anti-CD Toxin A Mab (clone TA7) |
MT-24TXA | 艱難梭菌毒素A重組蛋白(無毒性片段) | x1mg | C. difficile Toxin A recombinant protein (fragment without toxic activity) |
MT-18TB41 | 艱難梭菌毒素B抗(克隆TB41) | x1mg | Anti-CD Toxin B Mab (clone TB41) |
MT-18TB48 | 艱難梭菌毒素B抗(克隆TB48) | x1mg | Anti-CD Toxin B Mab (clone TB48) |
MT-24TXB | 艱難梭菌毒素B重組蛋白(無毒性片段) | x1mg | C. difficile Toxin B recombinant protein (fragment without toxic activity) |
MT-16GD10 | 艱難梭菌抗體(克隆GD10) | x1mg | Anti-GDH Mab (clone GD10) |
MT-25CEP | 空腸彎曲桿菌重組外膜蛋白 | x1mg | Campylobacter jejuni recombinant outer membrane protein |
MT-26VP6 | 輪狀病毒VP6重組蛋白 | x1mg | Rotavirus VP6 recombinant protein |
MT-16R15 | 輪狀病毒單克隆抗體(克隆R15) | x1mg | Anti-Rotavirus Mab (clone R15) |
MT-28SAGU | 滅活A鏈球菌抗原(天然提取物) | x1mg | Inactivated STREP A antigen (native extract) |
MT-28SEU | 滅活腸炎沙門氏菌抗原(天然提取物) | x1mg | Inactivated Salmonella enteritidis antigen (native extract) |
MT-28SBU | 滅活的鮑氏志賀氏菌抗原(天然提取物) | x1mg | Inactivated Shigella boydii antigen (native extract) |
MT-28EC7U | 滅活的大腸桿菌O157抗原(天然提取物) | x1mg | Inactivated E. coli O157 antigen (native extract) |
MT-28CCU | 滅活的大腸桿菌抗原(天然提取物) | x1mg | Inactivated Campylobacter coli antigen (native extract) |
MT-28LMU | 滅活的單核細胞增生李斯特菌抗原(天然提取物) | x1mg | Inactivated Listeria monocytogenes antigen (native extract) |
MT-28SPNU | 滅活的肺炎鏈球菌抗原(天然提取物) | x1mg | Inactivated Streptococcus pneumoniae antigen (native extract) |
MT-28SFU | 滅活的福氏志賀氏菌抗原(天然提取物) | x1mg | Inactivated Shigella flexneri antigen (native extract) |
MT-28CJU | 滅活的空腸彎曲桿菌抗原(天然提取物) | x1mg | Inactivated Campylobacter jejuni antigen (native extract) |
MT-28SDU | 滅活的痢疾志賀氏菌抗原(天然提取物) | x1mg | Inactivated Shigella dysenteriae antigen (native extract) |
MT-28LNU | 滅活的嗜肺軍團菌抗原(天然提取物) | x1mg | Inactivated Legionella pneumophila antigen (native extract) |
MT-28STMU | 滅活的鼠傷寒沙門氏菌抗原(天然提取物) | x1mg | Inactivated Salmonella typhimurium antigen (native extract) |
MT-28SSU | 滅活的宋內氏志賀菌抗原(天然提取物) | x1mg | Inactivated Shigella sonnei antigen (native extract) |
MT-28PECU | 滅活的幽門螺桿菌抗原(天然提取物) | x1mg | Inactivated H. pylori antigen (native extract) |
MT-29RVV | 滅活呼吸道合胞病毒抗原(天然提取物) | x1mg | Inactivated RSV antigen (native extract) |
MT-28SPAU | 滅活沙門氏菌副傷寒A抗原(天然提取物) | x1mg | Inactivated Salmonella paratyphi A antigen (native extract) |
MT-28SPBU | 滅活沙門氏菌副傷寒B抗原(天然提取物) | x1mg | Inactivated Salmonella paratyphi B antigen (native extract) |
MT-28STU | 滅活傷寒沙門氏菌抗原(天然提取物) | x1mg | Inactivated Salmonella typhi antigen (native extract) |
MT-28YE3U | 滅活小腸結腸炎耶爾森氏菌O:3抗原(天然提取物) | x1mg | Inactivated Yersinia enterocolitica O:3 antigen (native extract) |
MT-28YE9U | 滅活小腸結腸炎耶爾森氏菌O:9抗原(天然提取物) | x1mg | Inactivated Yersinia enterocolitica O:9 antigen (native extract) |
MT-29KOE | 滅活小球隱孢子蟲抗原(天然提取物) | x1mg | Inactivated Cryptosporidium parvum antigen (native extract) |
MT-25EDP | 內阿米巴重組蛋白 | x1mg | Entamoeba dispar recombinant protein |
MT-25NGI1 | 諾如病毒GI.1重組P結構域 | x1mg | Norovirus GI.1 recombinant P domain |
MT-31NGA | 諾如病毒GI.1重組VLP | x1mg | Norovirus GI.1 recombinant VLP |
MT-25NGI3 | 諾如病毒GI.3重組P結構域 | x1mg | Norovirus GI.3 recombinant P domain |
MT-25NGII10 | 諾如病毒GII.10重組P結構域 | x1mg | Norovirus GII.10 recombinant P domain |
MT-25NGII17 | 諾如病毒GII.17重組P結構域 | x1mg | Norovirus GII.17 recombinant P domain |
MT-25NGII14 | 諾如病毒GII.4重組P結構域 | x1mg | Norovirus GII.4 recombinant P domain |
MT-31NPA | 諾如病毒GII.4重組VLP | x1mg | Norovirus GII.4 recombinant VLP |
MT-18NP8 | 諾如病毒GII單克隆抗體(克隆NP8) | x1mg | Anti-Norovirus GII Mab (clone NP8) |
MT-18NG28 | 諾如病毒GI單克隆抗體(克隆NG28) | x1mg | Anti-Norovirus GI Mab (clone NG28) |
MT-25HCP | 人類鈣衛蛋白重組蛋白 | x1mg | Human Calprotectin recombinant protein |
MT-29HLF | 人乳鐵蛋白蛋白質(天然提取物) | x1mg | Human Lactoferrin protein (native extract) |
MT-29HHB | 人血紅蛋白蛋白質(天然提取物) | x1mg | Human Haemoglobin protein (native extract) |
MT-29HTF | 人轉鐵蛋白蛋白質(天然提取物) | x1mg | Human Transferrin protein (native extract) |
MT-20TSS | 溶血性A鏈球菌抗體 | x1mg | Anti-Strep A Pab |
MT-25EHP | 溶組織內阿米巴重組蛋白 | x1mg | Entamoeba histolytica recombinant protein |
MT-16LC16 | 乳鐵蛋白單抗(克隆LC16) | x1mg | Anti-Lactoferrin Mab (clone LC16) |
MT-16LC4 | 乳鐵蛋白單抗(克隆LC4) | x1mg | Anti-Lactoferrin Mab (clone LC4) |
MT-18LN14 | 嗜肺軍團菌單抗(克隆LN14) | x1mg | Anti-Legionella pneumophila Mab (clone LN14) |
MT-18LN29 | 嗜肺軍團菌單抗(克隆LN29) | x1mg | Anti-Legionella pneumophila Mab (clone LN29) |
MT-16CA29 | 彎曲桿菌抗體(克隆ECA29) | x1mg | Anti-Campylobacter Mab (clone CA29) |
MT-25CCP | 彎曲桿菌重組外膜蛋白 | x1mg | Campylobacter coli recombinant outer membrane protein |
MT-25HEX | 腺病毒HEXON重組蛋白 | x1mg | Adenovirus HEXON recombinant protein |
MT-18A14 | 腺病毒單克隆抗體(克隆A14) | x1mg | Anti-Adenovirus Mab (clone A14) |
MT-18A15 | 腺病毒單克隆抗體(克隆A15) | x1mg | Anti-Adenovirus Mab (clone A15) |
MT-18A15 | 腺病毒抗體(克隆A15) | x1mg | Anti-Adenovirus Mab (clone A15) |
MT-25HEXR | 腺病毒六鄰體重組蛋白 | x1mg | Adenovirus HEXON recombinant protein |
MT-18AT18 | 星狀病毒單克隆抗體(克隆AT18) | x1mg | Anti-Astrovirus Mab (clone AT18) |
MT-18AT8 | 星狀病毒單克隆抗體(克隆AT8) | x1mg | Anti-Astrovirus Mab (clone AT8) |
MT-25AST | 星狀病毒衣殼重組蛋白 | x1mg | Astrovirus capsid recombinant protein |
MT-16F22 | 血紅蛋白單抗(克隆F22) | x1mg | Anti-Haemoglobin Mab (clone F22) |
MT-18YB91 | 乙型流感病毒單抗(克隆YB91) | x1mg | Anti-Influenza B Mab (clone YB91) |
MT-25FBN | 乙型流感病毒重組核蛋白 | x1mg | Influenza B recombinant nucleoprotein |
MT-18K31 | 隱球菌抗體(克隆K31) | x1mg | Anti-Crypto Mab (clone K31) |
MT-25PCH | 幽門螺桿菌重組外膜蛋白 | x1mg | H. pylori recombinant outer membrane protein |
MT-16P2 | 幽門螺旋桿菌抗體(克隆P2)HP抗體 | x1mg | Anti-H. pylori Mab (clone P2) |
西班牙
美國亞利桑那州立大學宇宙學家Paul Davies和同事提出一個備受爭議的結論,癌癥是人體細胞試運轉“安全模式”,如同計算機系統在面臨外部威脅時試著保護自己那樣。
宇宙學家提出疾病起源新理論
該理論主要基于癌癥的進化,如果該理論正確,他們的模型提示,氧氣治療、感染病毒或細菌等一些非傳統療法可能尤其有效。
癌癥是人體細胞試運轉“安全模式”所產生的嗎,就像受損計算機系統在面臨外部威脅時試著保護自己那樣?這是美國亞利桑那州立大學宇宙學家Paul Davies和同事得出的結論,他們提出了一個備受爭議的癌癥起源新理論。該理論主要基于癌癥的進化根源。如果該理論正確,他們的模型提示,氧氣治療和感染病毒或細菌的一些非傳統療法可能尤其有效。
乍看之下,Davies似乎不像“癌癥戰爭”中的戰士,他是物理學出身,而非生物醫學。但是,大約7年前,他被邀請在亞利桑那州建立一個新機構——由國立癌癥研究所資助的12所機構中的1個,以便將物理學家和腫瘤學家聯合在一起,發現該疾病的新視角。“我們被要求從上到下重新思考癌癥。”Davies說。
隨后,Davies與澳大利亞國立大學天體生物學家Charley Lineweaver和英國倫敦健康科學中心腫瘤學家Mark Vincent展開合作,提出了“返祖現象”模式,將癌癥定位為古老“預編”特性的重新表達。在上個月發表于《生物學論文集》的新研究中,該研究小組指出,因為癌癥出現在許多動物、植物和人類中,那么它必須從億萬年前開始進化,那時生物擁有共同的單細胞祖先。
在那時,細胞受益于永生,或無限增殖能力,正如癌癥那樣。但當復雜的多細胞生物開始出現,“‘永生’被轉包給卵子和抗原抗體。”Davies說,不涉及繁衍的體細胞不再需要這種機能。
該研究小組提出的假設是,當健康細胞面臨環境威脅時,例如輻射或生活因素,細胞能夠回復到“預編的安全模式”。這樣一來,細胞會拋棄更高的機能,并將它們的休眠能力切換至增殖能力,以便存活下來。“癌癥是一種自動防障功能,”Davies提到,“一旦這個子程序被觸發,就會冷酷地運行該程序。”
9月11日,在英國帝國理工學院舉辦的一個醫學工程會議上,Davies描述了一系列基于這種返祖現象的癌癥療法。Davies指出,與簡單地攻擊癌癥復制能力不同,該模型揭示了“癌癥的阿喀琉斯之踵”。例如,如果該理論正確,那么癌癥進化初期地球的環境更酸且氧氣更稀薄。因此,研究人員預測,利用高水平氧氣和在飲食中加入還原糖以降低酸性,能夠抑制腫瘤并引起腫瘤收縮。
西班牙
想了解更多的產品及服務請掃描下方二維碼:
【公司名稱】 廣州健侖生物科技有限公司
【市場部】 楊永漢
【】
【騰訊 】 2042552662
【公司地址】 廣州清華科技園創新基地番禺石樓鎮創啟路63號二期2幢101-103室
Paul Davies, an ASU cosmologist at the University of Arizona, and his colleagues came up with the most controversial conclusion that cancer is a "safe mode" of human cell testing, just as computer systems try to protect themselves in the face of external threats.
Cosmologists put forward a new theory of the origin of disease
The theory is based primarily on the evolution of cancer and if the theory is correct, their models suggest that some unconventional therapies such as oxygen therapy, infection with viruses or bacteria may be particularly effective.
Is cancer a "safe mode" of human cell commissioning, just as damaged computer systems try to protect themselves against external threats? This is the conclusion of cosmologist Paul Davies and colleagues at Arizona State University, They put forward a controversial new theory of cancer origin. The theory is based primarily on the evolutionary causes of cancer. If the theory is correct, their models suggest that oxygen therapy and some unconventional therapies that affect the virus or bacteria may be particularly effective.
At first glance, Davies does not seem like a warrior in the "cancer war", he is a physics background, rather than biomedical. However, about seven years ago he was invited to establish a new agency in Arizona, one of 12 institutions funded by the National Cancer Institute, to bring together physicists and oncologists to discover the disease New perspective. "We were asked to rethink the cancer from top to bottom," Davies said.
Davies then collaborated with astrobiologist Charley Lineweaver of the Australian National University and Mark Vincent, an oncologist at the London-based Health Science Center, to propose a "return to ancestor" paradigm that positions cancer as a re-expression of the ancient "pre-dated" nature. In a new study published in the Proceedings of Biology last month, the team pointed out that because cancer appears in many animals, plants and humans, it must evolve hundreds of millions of years ago when the creatures have common Single cell ancestor.
At that time, cells benefit from eternal life, or infinite proliferative capacity, just as cancer does. But when complex multicellular organisms begin to emerge, "Immortality" is subcontracted to the egg and antigenic antibodies, Davies said, not involving multiplying somatic cells that are no longer needed for this function.
The team's hypothesis is that when healthy cells are exposed to environmental threats, such as radiation or life, cells can revert to a "pre-programmed security model." As a result, cells discard higher functions and switch their dormancy to proliferative capacity in order to survive. "Cancer is an automatic barrier," Davies said. "Once the subroutine is triggered, it runs coldly."
On September 11, at a medical engineering conference organized by Imperial College London, Davies described a series of cancer therapies based on this return phenomenon. Davies points out that unlike a simple attack on cancer replication, the model reveals "the Achilles heel of cancer." For example, if the theory is correct, the Earth's environment is more acidic and oxygenier at the beginning of cancer's evolution. Therefore, the researchers predicted that the use of high levels of oxygen and added to the diet reducing sugar to reduce acidity, can inhibit the tumor and cause tumor shrinkage.
請輸入賬號
請輸入密碼
請輸驗證碼
以上信息由企業自行提供,信息內容的真實性、準確性和合法性由相關企業負責,智慧城市網對此不承擔任何保證責任。
溫馨提示:為規避購買風險,建議您在購買產品前務必確認供應商資質及產品質量。